Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine

Alicia Gonzalez-Martinez1, Eva Rodríguez Vázquez2, Henar de la Red Gallego2

  • 1Headache Unit, Neurology Department, Hospital Universitario de La Princesa & Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain.

Headache
|November 7, 2019
PubMed
Abstract

Insights

This study found that a dependent personality trait is linked to a poorer response to onabotulinumtoxin A (onabotA) treatment in chronic migraine patients. Understanding personality traits may help predict treatment outcomes for onabotA in migraine management.

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Medicine

Background:

  • Chronic migraine (CM) patients may exhibit anxious or obsessive personality traits.
  • Previous research has not explored the impact of personality on onabotulinumtoxin A (onabotA) efficacy in CM.
  • This study hypothesizes a link between Cluster C personality traits and non-response to onabotA.

Purpose of the Study:

  • To investigate the association between personality traits and treatment response to onabotulinumtoxin A (onabotA) in patients suffering from chronic migraine (CM).

Main Methods:

  • A case-control observational study involving 112 CM patients who underwent at least two onabotA treatment cycles.
  • OnabotA response was defined as a ≥50% reduction in monthly migraine days.
  • Personality traits were assessed using the validated Salamanca questionnaire.

Main Results:

  • 85.7% of patients (96/112) responded to onabotA treatment.
  • A dependent personality trait was significantly associated with non-response to onabotA (P=.008; OR: 0.223).
  • No significant associations were found between other personality traits or confounders and onabotA response.

Conclusions:

  • This is the first study to suggest that personality traits can predict onabotA response in chronic migraine patients.
  • The presence of a dependent personality trait in CM patients is linked to a lower likelihood of responding to onabotA treatment.

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Stress Prevention and Stress Management Techniques II01:23

Stress Prevention and Stress Management Techniques II

Personality types, particularly Type A and Type B, significantly influence how individuals respond to stress. These personality distinctions are marked by varying levels of ambition, competitiveness, and coping styles, all of which shape an individual's resilience to stressors.
Type A Personality: Driven and Easily Stressed
Individuals with Type A personalities are often highly competitive and ambitious and operate with a strong sense of urgency. Commonly labeled as...
464